You are here
Convenience, Compliance and Overcoming Clinical Inertia for Primary Care Physicians
This course reviews the practical aspects of basal insulin-glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and shows how fixed-dose combination therapies provide added convenience that may help overcome clinical inertia related to insulin therapy. Clinical data will be presented to demonstrate how the efficacy and safety of basal insulin-GLP-1 receptor agonist combination therapy surpasses that of the individual components. After completing the course, participants will be able to identify patients for whom treatment with basal insulin-GLP-1 receptor agonist combination therapy may be a viable option, and know how to best manage these patients.
Basal Insulin–GLP-1 RA Combination Therapy: Convenience, Compliance, and Overcoming Clinical Inertia
In this webcast, Professor Khunti addresses the issue of clinical inertia, and discusses why patients often do not achieve glycaemic targets. He also discusses the rationale for earlier insulin initiation and how clinical inertia may be overcome.
In this roundtable discussion, Professor Wilding, Professor Cos, and Professor Harris discuss different oral and injectable therapies and their advantages and limitations. They also talk about the practical considerations when choosing the best therapy for a patient and the potential of new fixed-dose basal insulin–GLP-1 RA combination therapy.